| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Centrally acting muscle relaxant (substance) |
Is a |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Skeletal muscle relaxant (substance) |
Is a |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| agent antirhumatismal |
Is a |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Smooth muscle relaxant (substance) |
Is a |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Uric acid drug poisoning NOS |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Other muscle drug poisoning |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| [X]Poisoning by other and unspecified drugs acting on muscles |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Muscle drug poisoning |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Poisoning caused by drug groups primarily affecting the musculoskeletal system |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Accidental probenecid poisoning |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Intentional probenecid poisoning |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| intoxication par le probénécide d'intention indéterminée |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Drug groups primarily affecting musculoskeletal system adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Drug for the treatment of gout adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Colchicum alkaloid adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Uricosuric agent adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Probenecid adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Sulfinpyrazone adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Xanthine oxidase inhibitor adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Gold adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Sodium aurothiomalate adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Auranofin adverse reaction |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Drug groups primarily affecting the musculoskeletal system allergy |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Drug for the treatment of gout allergy |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Allergy to Colchicum alkaloid (finding) |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Uricosuric agent allergy |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Allergy to probenecid |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Allergy to sulfinpyrazone |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Allergy to xanthine oxidase inhibitor |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Overdose of drug primarily affecting the musculoskeletal system |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Uric acid drug overdose |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Gold salt overdose |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Accidental gold salt overdose |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Intentional gold salt overdose |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Gold salt overdose of undetermined intent |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Allopurinol (substance) |
Is a |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Colchicine (substance) |
Is a |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Poisoning caused by probenecid (disorder) |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Poisoning by uric acid metabolism drug |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing hylan |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Hylan G-F 20 8mg/mL injection solution 2mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing Colchicum alkaloid (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Adverse reaction to central nervous system muscle-tone depressants |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Adverse reaction to central nervous system muscle-tone depressants NOS |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Adverse reaction to uric acid metabolism drug NOS |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Adverse reaction to water, mineral or uric acid metabolism drug NOS |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Adverse reaction to other muscle drugs |
Causative agent (attribute) |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| agent antigoutteux |
Is a |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing leflunomide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Penicillamine 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Penicillamine 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Penicillamine 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Leflunomide 10 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Leflunomide 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Leflunomide 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| groupes de médicaments agissant principalement sur l'appareil locomoteur |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing penicillamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Medicinal product acting as antirheumatic agent (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Penicillamine [metabolic] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Drugs used in musculoskeletal/joint disorders |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Rheumatic disease suppressants |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Penicillamine [musculoskeletal use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing precisely penicillamine 250 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Penicillamine 125 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing zafirlukast (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing leukotriene receptor antagonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Aminophylline 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| aminophylline 25 mg/mL, ampoule de 10 mL de solution pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Aminophylline 225mg modified release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Aminophylline 350mg modified release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Aminophylline 100mg modified release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| aminophylline 25 mg/mL, seringue préremplie de 10 mL de solution pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 10mg/5mL s/f oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing precisely theophylline monohydrate (as theophylline sodium glycinate) 12 milligram/1 milliliter conventional release oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 175mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 250mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 60mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 125mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 250mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 200mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 300mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Theophylline 400mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Ephedrine hydrochloride 11 mg and theophylline 120 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Ephedrine sulfate 15 mg and theophylline 120 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing montelukast (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Montelukast (as montelukast sodium) 10 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing precisely montelukast (as montelukast sodium) 5 milligram/1 each conventional release chewable tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Zafirlukast 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Aminophylline-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Aminophylline-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing 5-lipoxygenase inhibitor (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing aminophylline (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing theophylline (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing theophylline sodium glycinate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Respiratory smooth muscle relaxant |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Smooth muscle relaxant |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Guaifenesin 1200mg m/r/pseudoephedrine 120mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Guaifenesin 600mg m/r/pseudoephedrine 60mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Montelukast sodium 4mg oral granules |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
| Product containing precisely montelukast (as montelukast sodium) 4 milligram/1 sachet conventional release oral granules (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Some |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]